

Published studies relevant for Orthokine® (partial list, alphabetical order):

1. Alvarez-Camino JC et al.: Use of autologous conditioned serum (ORTHOKINE) for the treatment of the degenerative osteoarthritis of the temporomandibular joint. Review of the literature. *Med Oral Patol Oral Cir Bucal* (2013) 18 (3):433-438
2. Baltzer AWA et al: Intraartikuläre Therapie der Gonarthrose mit autologem Interleukin-1 Rezeptor Antagonisten (IL-1Ra). *Deutsche Zeitschrift für Sportmedizin* (2003) 54(6): 209-211
3. Baltzer AWA et al.: Autologous conditioned serum (Orthokine®) is an effective treatment for knee osteoarthritis. *Osteoarthritis and Cartilage* (2009) 17(2): 152-160
4. Baltzer AWA et al.: A new treatment for hip osteoarthritis: clinical evidence for the efficacy of autologous conditioned serum. *Orthop Rev* (2013) 5(2):e13
5. Baselga J. et al, 2015, Treatment of Osteoarthritis of the Knee with a Combination of Autologous Conditioned Serum and Physiotherapy: A Two-Year Observational Study. *PLoS ONE* 10(12): e0145551.
6. Becker C et al.: Efficacy of epidural perineural injections with autologous conditioned serum for lumbar radicular compression: an investigator-initiated, prospective, double-blind, reference-controlled study. *Spine* (2007) 32(17): 1803–1808
7. Chevalier X et al.: Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis & Rheumatism* (2009) 61(3): 344-352
8. Creaney L, Hamilton B: Growth factor delivery methods in the management of sports injuries: the state of play. *Br J Sports Med* (2008) 42: 314–320
9. Darabos N et al.: Correlation between synovial fluid and serum IL-1 β levels after ACL surgery - preliminary report. *International Orthopedics (SICOT)* (2009) 33: 413-418
10. Darabos N et al.: Intraarticular application of autologous conditioned serum (ACS) reduces bone tunnel widening after ACL reconstructive surgery in a randomized controlled trial. *Knee Surg Sports Traumatol Arthrosc* (2011) 19: 36-46
11. Fox BA, Stephens MM: Treatment of knee osteoarthritis with ORTHOKINE-derived autologous conditioned serum. *Expert Rev Clin Immunol* (2010) 6(3): 335-345
12. Frisbie DD et al.: Clinical, biochemical, and histologic effects of intra-articular administration of autologous conditioned serum in horses with experimentally induced osteoarthritis. *Am J Vet Res* (2007) 68(3): 290–296
13. Frizziero A et al.: Autologous conditioned serum for the treatment of osteoarthritis and other possible applications in musculoskeletal disorders. *Br Med Bull* (2013) 105:169-184
14. Glawe H: Orthokin®-Therapie: Autologes Conditioniertes Serum an der Wirbelsäule. Eine Anwendungsbeobachtung an 261 Patienten. Poster 2006
15. Hague BA: Clinical Impression of ORTHOKINE (IRAP) Treating Joint Disease in the Performance Horse. ACVS conference 2005, San Diego, USA
16. Heisterbach PE et al.: Effect of BMP-12, TGF- β 1 and autologous conditioned serum on growth factor expression in Achilles tendon healing. *Knee Surg Sports Traumatol Arthrosc* (2012) 20(10): 1907-1914
17. Jöstingmeier U: Vergleichende Betrachtung des Behandlungserfolges der intraartikulären kombinierten Behandlung mit Natriumhyaluronat und Betamethason mit der intraartikulären Behandlung mit autologem konditionierten Serum (IL-1Ra) bei Pferden mit positiver Hufgelenksanästhesie - Eine Anwendungsbeobachtung. *Inaugural-Dissertation* an der Freien Universität Berlin (2008) ISBN 978-3-86664-665-0
18. Levy E et al.: Intraartikuläre Behandlung mit autologem irap conditionierten Serum – Teil 1. *pferde spiegel* 3/2005: 120-124
19. Majewski M et al.: Accelerated Healing of the Rat Achilles Tendon in Response to Autologous Conditioned Serum. *The American Journal of Sports Medicine* (2009) 11: 2117-2125
20. Martinelli MJ et al.: Biochemical Characterization and Clinical Assessment of Autologous Conditioned Serum Treatment in Race Horses. Annual Meeting of the Orthopaedic Research Society 2008, San Francisco, USA

21. Meijer H et al.: The production of anti-inflammatory cytokines in whole blood by physico-chemical induction. *Inflamm Res* (2003) 52(10): 404–407
22. Morgenstern, D.R. et al. Adjunctive Biological Treatment for Degenerative Hip Disease with Focal Chondro Labral Defects ISHA Annual Meeting, Munich, Poster 58 (2013)
23. Moser C et al.: Die Rolle der Zytokine bei Knorpeldefekten und in der Knorpeltherapie. Interleukin-1 und TNF-a: Schlüsselfaktoren der Knorpeldestruktion. *Arthroskopie* (2005) 18(3): 181-185
24. Österdahl J: Evaluation of autologous conditioned serum. Degree project 2008:67 at Swedish University of Agricultural Sciences, Uppsala (2008) ISSN 1652-8697
25. Theodoridis T, Krämer J: Interleukin-1-Rezeptor-Antagonist-Protein (IRAP). In: *Injektionstherapie an der Wirbelsäule. Manual und Atlas*, 37-40. Georg Thieme Verlag (2006) ISBN 3-13-141041-8
26. Wehling P et al.: Autologous Conditioned Serum in the treatment of Orthopaedic diseases – The ORTHOKINE® Therapy. *Biodrugs* (2007) 21(5): 323–332
27. Wehling P et al.: Use of Autologous Conditioned Cell-free Serum (ORTHOKINE®) in Treating Osteoarthritis and Sciatic Back Pain. *European Musculoskeletal Review* (2009) 4(1): 8-11
28. Weinberger T: Klinische Erfahrungen mit der Anwendung von ACS/ORTHOKIN®/IRAP beim Pferd. *pferde spiegel* 3/2008
29. Weinberger T.: Clinical experience with ACS/ORTHOKINE/IRAP in horses. *Equine Sports Medicine* 3/2008
30. Weinberger T.: Regenerative Therapiemöglichkeiten beim Pferd – eine Übersicht. *pferde spiegel* 3/2008
31. Weisshaar MP, Gaji S: Signaling Proteins (Growth Factors and Cytokines) in Orthopaedics. Comparison of two blood processing techniques: ORTHOKINE® and ACP®. CORS congress 2013 Venice, Italy
32. Wright-Carpenter T et al.: Treatment of muscle injuries by local administration of autologous conditioned serum: animal experiments using a muscle contusion model. *Int J Sports Med* (2004) 25(8): 582–587
33. Wright-Carpenter T et al.: Treatment of muscle injuries by local administration of autologous conditioned serum: a pilot study on sportsmen with muscle strains. *Int J Sports Med* (2004) 25(8): 588–593